Deferasirox

Drug Profile

Deferasirox

Alternative Names: CGP-72670; Exjade; ICL-670; ICL-670A; Jadenu

Latest Information Update: 06 Apr 2017

Price : $50

At a glance

  • Originator Novartis
  • Class Benzoic acids; Small molecules; Triazoles
  • Mechanism of Action Chelating agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Iron overload
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Iron overload
  • Phase II Myelodysplastic syndromes
  • Discontinued Malaria

Most Recent Events

  • 05 Feb 2017 Novartis terminates a phase II trial for Myelodysplastic syndromes (Combination therapy) in USA (NCT02159040) as only one patient enrolled in the trial
  • 17 Jan 2017 The Scottish Medicines Consortium accepts deferasirox for routine use in treatment of Iron overload
  • 01 Jan 2017 Novartis terminated a phase II trial in Iron overload in Norway (PO) (NCT01892644)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top